High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02769-4
Abstract: Background Glioblastomas (GBMs) in patients harboring somatic or germinal mutations of mismatch-repair (MMR) genes exhibit a hypermutable phenotype. Here, we describe a GBM patient with increased tumor mutational burden and germline MMR mutations, treated using… read more here.
Keywords: pd1 therapy; cell; anti pd1; response ... See more keywords
Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Pediatric transplantation"
DOI: 10.1111/petr.14209
Abstract: BACKGROUND Immunotherapy, specifically immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD1), has recently received clinical approval for the treatment of adult hepatocellular carcinoma (HCC). However, the safety and efficacy of ICIs prior to… read more here.
Keywords: pd1 therapy; graft; pd1; anti pd1 ... See more keywords
Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Immunology Research"
DOI: 10.1155/2020/7890985
Abstract: Background The pathological subtype of osteosarcoma is one of the most common malignant bone tumors. Notably, chemotherapy-resistant metastatic osteosarcoma has been reported to cause significant mortality and shows poor prognosis with the currently available multidisciplinary… read more here.
Keywords: pd1 therapy; anti pd1; til; metastatic osteosarcoma ... See more keywords
Abstract A59: Targeting the glutamine dependent hexosamine biosynthesis pathway sensitizes pancreatic tumors to anti-PD1 therapy
Sign Up to like & getrecommendations! Published in 2020 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm18-a59
Abstract: Background: Pancreatic cancer is notoriously difficult to treat owing to its late detection, metastasis and increased therapeutic resistance, leading to a 5-year survival rate of 9%. Immune evasive microenvironment further contributes to challenges in developing… read more here.
Keywords: therapy; cancer; pd1 therapy; anti pd1 ... See more keywords
Neurotoxicity associated with anti-PD1 therapy: A multi-center case series.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e21641
Abstract: e21641Background: The anti-PD1 antibodies (PD1) pembrolizumab and nivolumab are now FDA-approved in multiple malignancies. With increased use, rarer immune-related adverse events (irAEs) not well c... read more here.
Keywords: pd1 therapy; therapy multi; anti pd1; multi center ... See more keywords
Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4518
Abstract: 4518Background: Mutation load and neoantigen burden predict benefit from anti-PD1 therapy across several cancers but are generally low in RCC. Pan-cancer comparisons highlight RCC for its enriched ... read more here.
Keywords: pd1 therapy; rcc; burden; cancer ... See more keywords
Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.876048
Abstract: Immunotherapy treatments, particularly immune checkpoint blockade, can result in benefits in clinical settings. But many pre-clinical and clinical studies have shown that resistance to anti-PD1 therapy frequently occurs, leading to tumor recurrence and treatment failure,… read more here.
Keywords: resistance anti; anti pd1; pd1 therapy; pd1 ... See more keywords
Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.955063
Abstract: Melanoma is a highly aggressive skin cancer, which, although highly immunogenic, frequently escapes the body’s immune defences. Immune checkpoint inhibitors (ICI), such as anti-PD1, anti-PDL1, and anti-CTLA4 antibodies lead to reactivation of immune pathways, promoting… read more here.
Keywords: anti pd1; gene; pd1 therapy; gene expression ... See more keywords